Examining the NUDT15 gene's role in inflammatory bowel disease in Taiwan
Official title: The Prevalence and Impacts of Nudix Hydrolase 15 (NUDT15) Gene Variants in Taiwanese Inflammatory Bowel Disease
Run by National Taiwan University Hospital · NCT06913998 · Data updated 2026-11-12
This study looks at how the NUDT15 gene affects children with inflammatory bowel disease in Taiwan to see if it can help improve their treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 1 Year to 25 Years |
| Sex | All |
| Enrollment | 65 (estimated) |
| Sponsor | National Taiwan University Hospital Academic / other |
| Locations | 1 site (Taipei) |
| Status | Recruiting |
| Started | December 27, 2023 |
| Main results expected | January 2026 |
| Study ends | November 2026 |
| Registry record updated | April 8, 2025 |
| Trial ID | NCT06913998 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals diagnosed with inflammatory bowel disease who are willing to undergo a blood test for genetic evaluation.
✕Probably not a fit
Patients who refuse to participate in the blood test for NUDT15 gene evaluation will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on patients diagnosed with inflammatory bowel disease (IBD) at National Taiwan University Children's Hospital. Participants will undergo a blood test to evaluate the NUDT15 gene, which is known to influence the risk of neutropenia when using thiopurines for treatment. The study aims to summarize the prevalence and impacts of NUDT15 gene variants in the context of IBD in Taiwan, analyzing the gene test results alongside other clinical data to improve treatment strategies.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and safer treatment options for patients with inflammatory bowel disease.
How similar studies have gone: Previous studies have indicated the significance of NUDT15 gene variants in Asian populations, suggesting that this approach is both relevant and potentially impactful.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants who are diagnosed with inflammatory bowel disease. Exclusion Criteria: * Participants who refused to have blood test for NUDT15 gene evaluation.
Where it's running
-
National Taiwan University Hospital
Taipei, Taiwan Recruiting
Study contacts
- Study coordinator: Wei-Ting Chen, MD
- Email: DBE98@tepch.gov.tw
- Phone: +886-2-2312-3456
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Long-Term Guselkumab Use in Adults with Inflammatory Bowel Disease
This study looks at how long adults with Crohn's disease or ulcerative colitis stay on guselkumab in real-world care.
-
Intestinal ultrasound-guided management for inflammatory bowel disease
This study tests if adding point-of-care intestinal ultrasound at every visit changes treatment decisions for adults with Crohn’s disease or ulcerative colitis undergoing disease assessment.
-
Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia
This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.
-
Low-dose liposomal amphotericin B to prevent invasive fungal infections in neutropenic children
This study tests whether giving a fixed low dose of liposomal amphotericin B can prevent invasive fungal infections in children aged 3–17 who are severely neutropenic after hematopoietic stem cell transplantation or similar high-risk conditions.
-
G-CSF–fusion protein to prevent chemotherapy neutropenia in children with sarcoma
This trial tests Albipagrastim alfa (QLC2519) in children with sarcoma to see if it helps prevent chemotherapy-induced neutropenia.
-
Resting energy use in kids with inflammatory bowel disease
This multicenter study will test the resting energy expenditure of children aged 6–17 with new IBD diagnoses to see how it relates to disease activity and treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.